Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5%

Rapport Therapeutics (NASDAQ:RAPP)’s stock price dropped 6.5% on Wednesday . The stock traded as low as $23.93 and last traded at $24.18. Approximately 90,930 shares were traded during trading, a decline of 63% from the average daily volume of 242,660 shares. The stock had previously closed at $25.87.

Wall Street Analyst Weigh In

RAPP has been the topic of several recent research reports. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective on the stock. TD Cowen initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating on the stock. Finally, Stifel Nicolaus initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective on the stock.

Rapport Therapeutics Trading Down 0.8 %

Insider Buying and Selling

In related news, Director James Healy bought 44,032 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the transaction, the director now directly owns 40,851 shares of the company’s stock, valued at $1,001,666.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.